How Is The Market Feeling About Abbott Laboratories?
Abbott Laboratories's (NYSE:ABT) short percent of float has fallen 7.69% since its last report. The company recently reported that it has 14.48 million shares sold short, which is 0.84% of all regular
QuidelOrtho Appoints Abbott Laboratories Executive as Next CEO
By Denny Jacob QuidelOrtho said Thursday that Brian Blaser has been appointed as its next chief executive. The in-vitro diagnostic technologies provider said Blaser, who was also appointed presiden
What the Options Market Tells Us About Abbott Laboratories
Deep-pocketed investors have adopted a bullish approach towards Abbott Laboratories (NYSE:ABT), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga u
El Stent Innovador Que Se Disuelve De Abbott Recibe La Aprobación De La FDA Para Arterias Por Debajo De La Rodilla.
Más de 20 millones de personas en Estados Unidos viven con enfermedad arterial periférica, pero las opciones de tratamiento han sido limitadas. El andamio bioabsorbible liberador de everólimus ESP
Investors in Abbott Laboratories (NYSE:ABT) Have Seen Respectable Returns of 48% Over the Past Five Years
If you buy and hold a stock for many years, you'd hope to be making a profit. But more than that, you probably want to see it rise more than the market average. Unfortunately for shareholders, while
DexCom, Insulet, Tandem Seen Benefitting the Most in Diabetes Survey - Wells Fargo
Abbott's Receives FDA Approval For Esprit BTK Everolimus Eluting Resorbable Scaffold System
More than 20 million people in the U.S. are living with peripheral artery disease (PAD) yet there have been limited treatment optionsThe first-of-its-kind Esprit BTK Everolimus Eluting Resorbable Scaf
Abbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee
ABT, DHR, DXCM: Which "Strong Buy" Healthcare Stock Has More Upside?
The healthcare scene is home to some pretty defensive companies that aren’t exactly shying away from medical innovation.
This Steel Maker's Buyback Backfired. How Not to Get Burned.
Problems at Cleveland-Cliffs and 3M highlight the dangers when chasing high dividend yields. One way to cut the risk: Focus on the most popular Dividend Aristocrats.
Europe In-Vitro Diagnostics (IVD) Markets, 2023-2024 & 2029 With Abbott, BioMerieux, Danaher, Hoffmann-La Roche, Bio-Rad, Siemens Healthineers, Thermo Fisher Scientific, and Diasorin Dominating
Investors Heavily Search Abbott Laboratories (ABT): Here Is What You Need to Know
Abbott Labs Is Maintained at Overweight by Barclays
Abbott Labs Is Maintained at Overweight by Barclays
Barclays: Maintaining the Abbott Laboratories (ABT.US) rating, adjusted from an increase to an increase in holdings rating, and the target price was adjusted from $141.00 to $140.00.
Barclays: Maintaining the Abbott Laboratories (ABT.US) rating, adjusted from an increase to an increase in holdings rating, and the target price was adjusted from $141.00 to $140.00.
Barclays Maintains Overweight on Abbott Laboratories, Lowers Price Target to $140
Barclays analyst Matt Miksic maintains Abbott Laboratories with a Overweight and lowers the price target from $141 to $140.
Protein Supplements Market Size Is Set to Grow by USD 9.45 Billion From 2023-2027, Abbott Laboratories, Amway Corp. and BioTech USA Korlatolt Felelossegu Tarsasag, and More to Emerge as Some of the Key Vendors, Technavio
The global protein supplements market size is estimated to grow by USD 9.45 bn from 2023 to 2027, according to Technavio. The market is estimated to...
Global Epilepsy Treatment Drugs Market Size To Exceed USD 12.1 Billion By 2033 | CAGR Of 4.36%
We Think Some Shareholders May Hesitate To Increase Abbott Laboratories' (NYSE:ABT) CEO Compensation
Should You Expect Accelerating Earnings Growth for Abbott Laboratories (ABT)?
Results: Abbott Laboratories Beat Earnings Expectations And Analysts Now Have New Forecasts
No Data